Clinical Trials
400 trialsContinuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
National Institutes of Health Clinical Center (CC)
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical Inc.
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Servier
Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
St. Jude Children's Research Hospital
E-STOP2
Hospital Universitari Vall d'Hebron Research Institute
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
National Hospital Organization Nagoya Medical Center
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Feasibility Neurocognitive Outcome After Transplant
Stanford University
OHGW-ACP
Azienda USL Reggio Emilia - IRCCS
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
University of Kansas Medical Center
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
APEX
Cogent Biosciences, Inc.
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma
St. Jude Children's Research Hospital
Durvalumab and Tremelimumab for Pediatric Malignancies
AstraZeneca
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
PRAGMATIC
The University of Queensland
QUATRO-APL
Quetzal Therapeutics
Massage Impact on Sleep in Pediatric Oncology
Children's Hospital of Philadelphia
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
UR-GOAL RCT
University of Rochester
LAUREL
Inmune Bio, Inc.
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
CLOVER-WaM
Cellectar Biosciences, Inc.
ACCESS
Center for International Blood and Marrow Transplant Research
OPTIC
Takeda
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Astellas Pharma Inc
Discontinuation Study
University College Cork
HORIZONS
Massachusetts General Hospital
DETERMINE
Cancer Research UK
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
National Institutes of Health Clinical Center (CC)
The Florida ASCENT Study
University of Florida
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
ReVenG
AbbVie
CRETI-NH
Baylor College of Medicine
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors
St. Jude Children's Research Hospital
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
Nanjing RegeneCore Biotech Co., Ltd.
CARE-RT
Jinnah Postgraduate Medical Centre
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
AbbVie